Holen Sie sich die Stockscreener-App
210.37
1.34%
3.045
Schlusskurs vom Vortag:
$207.32
Offen:
$206.01
24-Stunden-Volumen:
184.43K
Relative Volume:
0.08
Marktkapitalisierung:
$45.09B
Einnahmen:
$742.00K
Nettoeinkommen (Verlust:
$-1.37B
KGV:
-29.74
EPS:
-7.0731
Netto-Cashflow:
$-1.07B
1W Leistung:
+0.41%
1M Leistung:
+2.41%
6M Leistung:
+110.53%
1J Leistung:
+413.17%
1-Tages-Spanne:
$204.46
$213.00
1-Wochen-Bereich:
$204.46
$213.00
52-Wochen-Spanne:
$39.73
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
650-481-6801
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, MRNA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
210.37 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
523.00 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.20 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.04 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.94 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-02-27 | Fortgesetzt | UBS | Buy |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - The Manila Times
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal - Yahoo Finance
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough? - Yahoo Finance
Revolution Medicines Got Its Breakthrough—What Moves It Next? - MarketBeat
Revolution’s Rasonque Shows Promise In Lung Cancer - insights.citeline.com
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today - Benzinga
Revolution Medicines(RVMD.US) Director Sells US$11.38 Million in Common Stock - Moomoo
RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM - GuruFocus
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer - The Manila Times
Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC - Quiver Quantitative
An experimental lung cancer drug held disease in check for 89% of patients in one group. - Stock Titan
Revolution Medicines (RVMD) insider sale under preset trading plan - Stock Titan
Challenging Convention to Solve the Hardest Problems in Medicine – Revolution Medicines - Oncodaily
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals - BioSpace
Revolution Medicines: Benefit Vs Reality Compared To Peer Therapeutics (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines Enters Lease Agreements for New Headquarters in Redwood City - marketscreener.com
What Revolution Medicines (RVMD)'s RASONQUE Pancreatic Cancer Focus Means For Shareholders - webull.com
New pancreatic cancer pill priced at $480,000 per year - KTLA
Revolution Medicines (NASDAQ: RVMD) trust moves to sell 73,090 shares - Stock Titan
Revolution’s newly approved drug doubles pancreatic cancer survival time - Mugglehead Investment Magazine
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions - Seeking Alpha
StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy - Genetic Engineering and Biotechnology News
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer - TradingView
Revolution Medicines (RVMD) Falls as Investors Appear to Take Profits After FDA Approval - Quiver Quantitative
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug - Benzinga
Revolution Medicines stock hits all-time high at 220.8 USD - Investing.com
Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports - marketscreener.com
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer - Barchart.com
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug - Yahoo! Finance Canada
Revolution Medicines (RVMD) Gains FDA Approval for Rasonque, Sha - GuruFocus
US FDA approves Revolution Medicines' pancreatic cancer drug - marketscreener.com
Revolution Medicines (RVMD) CEO trades stock under preset 10b5-1 plan - Stock Titan
Revolution Medicines nears lease for 700,000-square-foot Redwood City campus - The Business Journals
Revolution Medicines (NASDAQ: RVMD) trust plans 3,000-share Rule 144 sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade - Stock Titan
Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale - Stock Titan
RVMD Maintained by Bernstein -- Price Target Raised to $179 - GuruFocus
REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151 - Bitget
Revolution Medicines (NASDAQ: RVMD) trust to sell 3,000 shares under Rule 144 - Stock Titan
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - AOL.com
Breakthrough Pancreatic Cancer Drug Maker Builds on Illinois Research Roots - Carle Illinois College of Medicine
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Revolution (RVMDW) Price and Levels: Advances 4.09% to $12.59 in Latest Trading; Technical Focus: the $11.96 to $13.22 Range Remains in Focus in the Available RecordBollinger Walk - Vinanet
Why Revolution Medicines (RVMD) Stock Is Up Today - Quiver Quantitative
Revolution Medicines stock hits all-time high at 208.77 USD - Investing.com
Revolution Medicines stock hits all-time high at 208.77 USD By Investing.com - Investing.com Australia
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.28%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):